Biolog-id Raises 30 Million Euros From Funds Managed by Xerys
Summary
PARIS--(BUSINESS WIRE)--Biolog-id, a global leader in the traceability and management of sensitive health products (red blood cells, plasma, platelets and chemotherapy preparations), is announcing a campaign to raise 30 million euros from Xerys Funds. With this campaign, Biolog-id aims to exceed €200 M in turnover by 2023 and to join the clan of French unicorns — unlisted companies worth more than a billion dollars. The funds gathered will enable us to accelerate the company’s international development through its main subsidiaries — North America, Middle East and Asia — and to extend the scope of action to other regions, in particular China. Today, the company is valued at 150 million euros by the strategy consulting firm Roland Berger to increase to over a billion in 2023, given its prospects for development and future results. Access to this essential data enables us to completely eliminate administration errors by ensuring that the right product is administered to the right patient and to check the product’s quality by guaranteeing its transport and storage conditions.